title: Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.
abstract: We describe a new generation of heterocyclic nonpeptide matrix metalloproteinase (MMP) inhibitors derived from a 6H-1,3,4-thiadiazine scaffold. A screening effort was utilized to identify some chiral 6-methyl-1,3,4-thiadiazines that are weak inhibitors of the catalytic domain of human neutrophil collagenase (cdMMP-8). Further optimization of the lead compounds revealed general design principles that involve the placement of a phenyl or thienyl group at position 5 of the thiadiazine ring, to improve unprimed side affinity; the incorporation of an amino group at position 2 of the thiadiazine ring as the chelating agent for the catalytic zinc; the placement of a N-sulfonamide-substituted amino acid residue at the amino group, to improve primed side affinity; and the attachment of diverse functional groups at position 4 or 5 of the phenyl or thienyl group at the unprimed side, to improve selectivity. The new compounds were assayed against eight different matrix metalloproteinases, MMP-1, cdMMP-2, cdMMP-8, MMP-9, cdMMP-12, cdMMP-13, cdMMP-14, and the ectodomain of MMP-14, respectively. A unique combination of the above-described modifications produced the selective inhibitor (2R)-N-[5-(4-bromophenyl)-6H-1,3,4-thiadiazin-2-yl]-2-[(phenylsulfonyl)amino]propanamide with high affinity for MMP-9 (K(i) = 40 nM). X-ray crystallographic data obtained for cdMMP-8 cocrystallized with N-allyl-5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-amine hydrobromide gave detailed design information on binding interactions for thiadiazine-based MMP inhibitors.
authors.affiliation: Abt. Biochemie I, Universität Bielefeld, Fakultät für Chemie, Universitätsstr. 25, D-33615 Bielefeld, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Schröder
authors.forename: A
authors.initials: A
authors.lastname: Henke
authors.forename: H
authors.initials: H
authors.lastname: Wenzel
authors.forename: H
authors.initials: H
authors.lastname: Brandstetter
authors.forename: H G
authors.initials: HG
authors.lastname: Stammler
authors.forename: A
authors.initials: A
authors.lastname: Stammler
authors.forename: W D
authors.initials: WD
authors.lastname: Pfeiffer
authors.forename: H
authors.initials: H
authors.lastname: Tschesche
mesh_terms: D001665:Binding Sites; D018360:Crystallography, X-Ray; D015195:Drug Design; D006801:Humans; D007700:Kinetics; D008958:Models, Molecular; D011480:Protease Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry; D011485:Protein Binding; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D013449:Sulfonamides / Q000138:chemical synthesis* / Q000737:chemistry; D013829:Thiadiazines / Q000138:chemical synthesis* / Q000737:chemistry
chemical_list: D011480:Protease Inhibitors; D013449:Sulfonamides; D013829:Thiadiazines